---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122297"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:44:09.042442+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports Q3 2024 net loss $88.1M; RLY-2608 shows 9.2-month median PFS

## Summary
- Net loss $88.1M ($0.63/share); revenue $0 vs $25.2M year ago (prior Genentech milestone).
- Cash $839.6M at Sep 30, 2024; expected to fund operations into H2 2027.
- RLY-2608 + fulvestrant interim data: 9.2-month median PFS, 33% ORR in heavily pre-treated PI3Kα-mutated breast cancer.
- Plan to initiate Phase 3 pivotal trial of RLY-2608 + fulvestrant in 2L breast cancer in 2025.
- Raised $230M in Sep 2024 follow-on; streamlined R&D with ~$50M annual savings, 15% workforce reduction.

## SEC filing metadata
- accession: 0000950170-24-122297
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024122297/0000950170-24-122297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024122297/rlay-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122297
- JSON: https://secwatch.observer/filing/0000950170-24-122297.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.